{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:25:53Z","timestamp":1785407153804,"version":"3.56.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["22K10547"],"award-info":[{"award-number":["22K10547"]}]},{"DOI":"10.13039\/501100007655","name":"Aichi Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Oral third-generation cephalosporins (3GCs) are not recommended for use owing to their low bioavailability and the risk of emergence of resistant microorganisms with overuse. A standardized and effective method for reducing their use is lacking. Here, in a 60-month, single-institution, interrupted time-series analysis, which was retrospectively conducted between April 1, 2017, and March 31, 2022, we evaluated the effectiveness of a four-phase intervention to reduce the use of 3GCs in patients at a cancer center: Phase 1 (pre-intervention), Phase 2 (review of clinical pathways), Phase 3 (establishment of infectious disease consultation service and implementation of antimicrobial stewardship program), and Phase 4 (educational lecture and pop-up displays for oral antimicrobials at the time of ordering). Although no significant changes were observed in Phases 3 and 4, the first intervention resulted in a significant decrease in the trend and level of days of therapy (DOT) for 3GCs. The level for cephalexin DOT and the trend for sulfamethoxazole-trimethoprim DOT increased in Phase 4, and the trend for amoxicillin and amoxicillin-clavulanate DOT increased in Phase 3. Macrolide DOT showed a decreasing trend in Phases 2 and 4 and decreasing and increased levels in Phases 3 and 4, respectively; no change was observed for quinolones. Actual and adjusted purchase costs of 3GCs decreased significantly during all study periods, while those for oral antimicrobials decreased in Phase 2, and actual purchase costs increased in Phases 3 and 4. No significant reduction in resistant organisms, length of hospital stay, or mortality was observed. This is the first study on the effects of oral 3GC reduction strategies in patients with cancer. We conclude that even facilities that substantially use antimicrobials can efficiently reduce the use of 3GCs.<\/jats:p>","DOI":"10.1371\/journal.pone.0281518","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T18:52:23Z","timestamp":1675968743000},"page":"e0281518","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Reduction strategies for inpatient oral third-generation cephalosporins at a cancer center: An interrupted time-series analysis"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6269-7884","authenticated-orcid":true,"given":"Naoya","family":"Itoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7003-4634","authenticated-orcid":true,"given":"Nana","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ishibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-2752","authenticated-orcid":true,"given":"Eiichi N.","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"pone.0281518.ref001","unstructured":"World Health Organization Global Action Plan on Antimicrobial Resistance, 2015 [cited 2021 December 25]. Available from: https:\/\/www.who.int\/antimicrobial-resistance\/global-action-plan\/en\/"},{"key":"pone.0281518.ref002","unstructured":"The Government of Japan NAP on Antimicrobial Resistance (AMR) 2016\u20132020 [cited 2021 December 25]. Available from: https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-10900000-Kenkoukyoku\/0000138942.pdf."},{"issue":"1","key":"pone.0281518.ref003","doi-asserted-by":"crossref","first-page":"e0263095","DOI":"10.1371\/journal.pone.0263095","article-title":"Effects of infectious disease consultation and antimicrobial stewardship program at a Japanese cancer center: An interrupted time-series analysis","volume":"17","author":"N Itoh","year":"2022","journal-title":"PLOS ONE"},{"issue":"1","key":"pone.0281518.ref004","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s12913-020-05380-6","article-title":"Infectious disease specialist consultations in a Japanese cancer center: A retrospective review of 776 cases","volume":"20","author":"N Itoh","year":"2020","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"pone.0281518.ref005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/jgf2.383","article-title":"Pulmonary infections mimicking malignancy on bronchoscopy: A retrospective single-center study in Japan","volume":"22","author":"N Itoh","year":"2020","journal-title":"J Gen Fam Med"},{"key":"pone.0281518.ref006","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jgar.2016.07.002","article-title":"Japanese antimicrobial consumption surveillance: First report on oral and parenteral antimicrobial consumption in Japan (2009\u20132013)","volume":"7","author":"Y Muraki","year":"2016","journal-title":"J Glob Antimicrob Resist"},{"key":"pone.0281518.ref007","unstructured":"The European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe, 2012 [cited 2021 December 12]. Available from: https:\/\/ecdc.europa.eu\/sites\/portal\/files\/media\/en\/publications\/Publications\/antimicrobial-consumption-europe-esac-net-2012.pdf. 2014."},{"key":"pone.0281518.ref008","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/512810","article-title":"European Surveillance of Antimicrobial Consumption Project Group. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries","volume":"44","author":"H Goossens","year":"2007","journal-title":"Clin Infect Dis"},{"key":"pone.0281518.ref009","unstructured":"Surveillance of antibiotic use by prefecture and age category, based on data from the NDB [cited 2021 December 25]. Available from: https:\/\/amrcrc.ncgm.go.jp\/surveillance\/010\/ref\/NDB_2013-2020.pdf"},{"issue":"4","key":"pone.0281518.ref010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jiph.2019.11.003","article-title":"\u03b2-Lactamase-non-producing ampicillin-resistant Haemophilus influenzae is acquiring multidrug resistance","volume":"13","author":"S Yamada","year":"2020","journal-title":"J Infect Public Health"},{"issue":"1","key":"pone.0281518.ref011","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/107662903764736337","article-title":"Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States","volume":"9","author":"K Hasegawa","year":"2003","journal-title":"Microb Drug Resist"},{"issue":"9","key":"pone.0281518.ref012","doi-asserted-by":"crossref","first-page":"e00851","DOI":"10.1128\/AAC.00851-18","article-title":"Multiclonal expansion and high prevalence of \u03b2-lactamase-negative Haemophilus influenzae with high-level ampicillin resistance in Japan and susceptibility to quinolones","volume":"62","author":"H Honda","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0281518.ref013","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ped.12781","article-title":"Nationwide survey of Streptococcus pneumoniae drug resistance in the pediatric field in Japan","volume":"58","author":"T Okada","year":"2016","journal-title":"Pediatr Int"},{"issue":"Pt 7","key":"pone.0281518.ref014","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1099\/jmm.0.059279-0","article-title":"Community spread of extended-spectrum \u03b2-lactamase-producing Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis: A long-term study in Japan","volume":"62","author":"Y Chong","year":"2013","journal-title":"J Med Microbiol"},{"issue":"2","key":"pone.0281518.ref015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jiac.2016.08.010","article-title":"Epidemiology of extended-spectrum beta-lactamase (ESBL) producing Escherichia coli in Japan: Characteristics of community-associated versus healthcare-associated ESBL E. coli","volume":"23","author":"K Hayakawa","year":"2017","journal-title":"J Infect Chemother"},{"key":"pone.0281518.ref016","first-page":"1","article-title":"Association between extended-spectrum \u03b2-lactamase-producing Escherichia coli and oral third-generation cephalosporins","author":"H Hosokawa","year":"2021","journal-title":"Infect Control Hosp Epidemiol"},{"key":"pone.0281518.ref017","doi-asserted-by":"crossref","DOI":"10.1201\/9781498747967","volume-title":"Kucers\u2019 the use of antibiotics","author":"M Lindsay Grayson","year":"2017","edition":"7"},{"issue":"8","key":"pone.0281518.ref018","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1503\/cmaj.071812","article-title":"Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection","volume":"179","author":"S Dial","year":"2008","journal-title":"CMAJ"},{"issue":"6","key":"pone.0281518.ref019","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s10072-012-0939-7","article-title":"Acquired encephalopathy associated with carnitine deficiency after cefditoren pivoxil administration","volume":"33","author":"H Kim","year":"2012","journal-title":"Neurol Sci"},{"issue":"19","key":"pone.0281518.ref020","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2169\/internalmedicine.2339-18","article-title":"Relapsing hypoglycemia associated with hypocarnitinemia following treatment with cefcapene pivoxil in an elderly man","volume":"58","author":"S Hanai","year":"2019","journal-title":"Intern Med"},{"issue":"6","key":"pone.0281518.ref021","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s15010-019-01362-x","article-title":"Efficacy of educational intervention on reducing the inappropriate use of oral third-generation cephalosporins","volume":"47","author":"A Uda","year":"2019","journal-title":"Infection"},{"issue":"6","key":"pone.0281518.ref022","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41393-020-0416-8","article-title":"Use of oral third generation cephalosporins and quinolones and occurrence of antibiotic-resistant strains in the neurogenic bladder (NB) outpatient setting: A retrospective chart audit","volume":"58","author":"K Kitagawa","year":"2020","journal-title":"Spinal Cord"},{"key":"pone.0281518.ref023","article-title":"Measures Against Antimicrobial Resistance in Children in Japan: Current Status and Future Prospects","author":"Y Kusama","year":"2022","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"pone.0281518.ref024","doi-asserted-by":"crossref","first-page":"E115","DOI":"10.1017\/ash.2022.251","article-title":"Impact of targeted intervention using a collaborative approach for oral third-generation cephalosporins: An interrupted time-series analysis","volume":"2","author":"R Yamaguchi","year":"2022","journal-title":"Antimicrobial Stewardship & Healthcare Epidemiology"},{"key":"pone.0281518.ref025","unstructured":"Centers for Disease Control and Prevention. Multidrug-resistant organism and Clostridioides difficile infection (MDRO\/CDI) module. Updated; January 2020 [cited 2020 July 15]. Available from: https:\/\/www.cdc.gov\/nhsn\/PDFs\/pscManual\/12pscMDRO_CDADcurrent.pdf."},{"key":"pone.0281518.ref026","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, M100-S22. Wayne: CLSI; 2012."},{"key":"pone.0281518.ref027","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, M100-S31. Wayne: CLSI; 2021."},{"key":"pone.0281518.ref028","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/j.1875-9114.2012.01162.x","article-title":"Antimicrobial stewardship in patients with cancer","volume":"32","author":"FP Tverdek","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"3","key":"pone.0281518.ref029","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, Version 1.2020","volume":"18","author":"JA Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"pone.0281518.ref030","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America","volume":"52","author":"AG Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"pone.0281518.ref031","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"TF Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0281518.ref032","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jiac.2020.10.010","article-title":"The effectiveness of prescription support and treatment reporting system on the appropriate usage of oral third-generation cephalosporins","volume":"27","author":"T Kato","year":"2021","journal-title":"J Infect Chemother"},{"key":"pone.0281518.ref033","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.cmi.2020.10.024","article-title":"A call for antimicrobial stewardship in patients with COVID-19: A nationwide cohort study in Korea","volume":"27","author":"DH Shin","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"pone.0281518.ref034","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jhin.2020.10.002","article-title":"Antimicrobial stewardship: A COVID casualty?","volume":"106","author":"C Lynch","year":"2020","journal-title":"J Hosp Infect"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0281518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T18:52:53Z","timestamp":1675968773000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0281518"}},"subtitle":[],"editor":[{"given":"Iddya","family":"Karunasagar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0281518","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]}}}